Levodopa: Uses, Dosage & Side Effects
The gold-standard dopamine precursor for treating the motor symptoms of Parkinson's disease
Levodopa is the most effective medication for treating the motor symptoms of Parkinson's disease, including tremor, rigidity, and bradykinesia (slowness of movement). As a natural precursor to dopamine, levodopa crosses the blood-brain barrier and is converted to dopamine in the brain, replenishing the depleted neurotransmitter stores that cause parkinsonian symptoms. It is always co-administered with a peripheral decarboxylase inhibitor (carbidopa or benserazide) to maximize brain delivery and minimize peripheral side effects. Levodopa is listed on the WHO Model List of Essential Medicines and requires a prescription worldwide.
Quick Facts: Levodopa
Key Takeaways
- Levodopa remains the most effective symptomatic treatment for Parkinson's disease and is the gold-standard medication recommended by the Movement Disorder Society (MDS), NICE, and WHO guidelines.
- It must always be combined with a decarboxylase inhibitor (carbidopa or benserazide) to prevent peripheral breakdown, reduce nausea, and increase the amount of dopamine reaching the brain.
- Long-term use can lead to motor complications including dyskinesias (involuntary movements) and motor fluctuations (wearing-off and on-off phenomena), which affect up to 50% of patients after 5 years.
- Inhaled levodopa (Inbrija) provides rapid rescue therapy for off-periods, with symptom improvement typically within 10-15 minutes, used alongside regular oral levodopa treatment.
- Never stop levodopa abruptly, as sudden withdrawal can trigger a life-threatening condition resembling neuroleptic malignant syndrome with high fever, severe rigidity, and altered consciousness.
What Is Levodopa and What Is It Used For?
Levodopa (L-DOPA, or L-3,4-dihydroxyphenylalanine) is the metabolic precursor of dopamine, the neurotransmitter that is progressively lost in Parkinson's disease due to degeneration of dopaminergic neurons in the substantia nigra pars compacta of the brain. Unlike dopamine itself, levodopa can cross the blood-brain barrier, where it is subsequently converted to dopamine by the enzyme aromatic amino acid decarboxylase (AADC), also known as DOPA decarboxylase. This conversion replenishes the depleted dopamine stores in the striatum, the brain region responsible for coordinating smooth, purposeful movements.
First introduced for clinical use in the 1960s following the groundbreaking work of Oleh Hornykiewicz and subsequent clinical trials by George Cotzias, levodopa represented a revolutionary advance in neurology. The dramatic improvement it produced in patients with severe Parkinson's disease was described as one of the most remarkable therapeutic achievements in the history of medicine. Today, more than five decades later, levodopa remains the single most effective medication for treating the motor symptoms of Parkinson's disease, and it is included on the World Health Organization's Model List of Essential Medicines.
Levodopa is indicated for the symptomatic treatment of Parkinson's disease (also called paralysis agitans or idiopathic parkinsonism). It is effective against all the cardinal motor features of the disease, including resting tremor, muscular rigidity, bradykinesia (slowness of movement), and postural instability. The response to levodopa is often used as a diagnostic criterion for Parkinson's disease: a robust improvement in motor symptoms with levodopa therapy supports the diagnosis, while a poor or absent response suggests an alternative parkinsonian disorder such as progressive supranuclear palsy (PSP) or multiple system atrophy (MSA).
When levodopa is taken orally without a decarboxylase inhibitor, approximately 95% of the dose is converted to dopamine in the peripheral circulation before it can reach the brain. This peripheral conversion leads to significant nausea, vomiting, and cardiovascular side effects (such as orthostatic hypotension and cardiac arrhythmias) while providing minimal therapeutic benefit to the brain. For this reason, levodopa is always co-administered with a peripheral decarboxylase inhibitor — either carbidopa (used in Sinemet and Stalevo) or benserazide (used in Madopark). These inhibitors block the peripheral conversion of levodopa to dopamine, thereby increasing the proportion of levodopa that reaches the brain from approximately 5% to 30-40%, allowing lower doses to be effective and substantially reducing peripheral side effects.
In addition to standard oral tablet and capsule formulations, levodopa is available in several specialized delivery forms designed to address specific clinical needs. Extended-release (depot) capsules provide a more gradual and sustained release of the medication, which can help reduce motor fluctuations. Intestinal gel formulations (Duodopa) deliver levodopa/carbidopa continuously through a portable pump directly into the duodenum via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube, intended for patients with advanced Parkinson's disease and severe motor fluctuations. An inhaled form of levodopa (Inbrija) allows rapid pulmonary absorption for rescue treatment of off-periods, with effects beginning within approximately 10-15 minutes.
What Should You Know Before Taking Levodopa?
Contraindications
There are specific clinical situations where levodopa must not be used. Understanding these contraindications is critical for safe prescribing and the prevention of serious adverse events. You should not take levodopa if any of the following apply:
- Hypersensitivity: Known allergy to levodopa or any excipient in the formulation.
- Narrow-angle glaucoma: Levodopa is contraindicated in patients with untreated narrow-angle (closed-angle) glaucoma. Symptoms of this condition include blurred vision, red eyes, severe eye pain, intense headache, seeing halos around lights, dilated pupils, and nausea. If you experience these symptoms, seek emergency medical care immediately.
- Pheochromocytoma: A rare tumor of the adrenal gland that produces excessive catecholamines. Levodopa can trigger a hypertensive crisis in these patients.
- Non-selective MAO inhibitors: Concurrent use with non-selective monoamine oxidase inhibitors (such as isocarboxazid and phenelzine) is strictly contraindicated due to the risk of hypertensive crisis. These medications must be discontinued at least 14 days before starting levodopa.
- History of neuroleptic malignant syndrome (NMS): Patients with a prior episode of NMS or non-traumatic rhabdomyolysis should not receive levodopa.
Seek immediate medical attention if you experience severe muscle rigidity, tremors, agitation, confusion, fever, rapid heartbeat, or dizziness with fainting upon standing. These may be symptoms of withdrawal hyperpyrexia, a potentially life-threatening condition that can occur if levodopa is suddenly stopped or rapidly reduced.
Warnings and Precautions
Before starting levodopa therapy, inform your doctor if you have, have ever had, or develop any of the following conditions, as additional monitoring or dose adjustments may be required:
- Respiratory conditions: Asthma, chronic obstructive pulmonary disease (COPD), or other long-term lung diseases, particularly if using the inhaled formulation (Inbrija).
- Psychiatric disorders: Any severe mental health condition, including psychosis, as levodopa can exacerbate psychiatric symptoms and cause hallucinations, delusions, or paranoia.
- Cardiovascular disease: History of heart attack (myocardial infarction) or irregular heart rhythm (arrhythmias). Your doctor will monitor you carefully when treatment is started.
- Peptic ulcer disease: Active or history of stomach or intestinal ulcers, as levodopa can increase the risk of gastrointestinal bleeding.
- Glaucoma: Open-angle glaucoma requires regular monitoring of intraocular pressure during levodopa therapy.
- Kidney disease: Severe renal impairment may affect drug clearance.
- Liver disease: Severe hepatic impairment requires careful monitoring.
Levodopa may cause impulse control disorders including pathological gambling, compulsive shopping or spending, binge eating, and hypersexuality (abnormally increased sex drive). If you or your family notice any of these behaviors, inform your doctor immediately, as treatment adjustments may be needed.
Tell your doctor if you experience sudden onset of sleep or excessive drowsiness while taking levodopa. You should not drive or operate machinery until these episodes have been resolved, as they pose a serious risk of accidents. Changes in mental state including hallucinations (seeing or hearing things that are not real), confusion, difficulty sleeping, vivid or violent dreams, anxiety, depression, paranoia, or delusional thinking should also be reported promptly.
Levodopa may cause or worsen dyskinesias (abnormal involuntary movements), dizziness when standing up (orthostatic hypotension), and worsening of respiratory symptoms. Regular monitoring for melanoma (a type of skin cancer) is recommended, as epidemiological studies have suggested a possible association between Parkinson's disease and melanoma. Inform your doctor of any new or changing skin lesions.
Pregnancy and Breastfeeding
Levodopa is not recommended during pregnancy or in women of childbearing potential who are not using effective contraception, as animal studies have shown potential risks to the developing fetus. If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using this medication. Women should not breastfeed while taking levodopa, as the drug may pass into breast milk and suppress lactation.
Driving and Operating Machinery
Levodopa can cause significant drowsiness, dizziness, and sudden episodes of sleep onset (sleep attacks) without preceding warning signs of drowsiness. These effects are particularly dangerous because they can occur during activities requiring full alertness, such as driving a vehicle or operating heavy machinery. You must not drive or operate machinery if you experience these effects. You should wait until these episodes have completely resolved before resuming such activities, as you could endanger yourself and others.
Laboratory Tests
Long-term levodopa therapy requires periodic monitoring of cardiac, hepatic, renal, and hematological function. Levodopa can interfere with certain laboratory test results, including urine tests for glucose, ketones, and catecholamines, as well as blood tests for uric acid. Always inform your healthcare provider or laboratory that you are taking levodopa before undergoing any blood or urine tests to ensure accurate interpretation of results.
How Does Levodopa Interact with Other Drugs?
Drug interactions with levodopa are clinically important because they can either reduce its therapeutic effectiveness or increase the risk of serious adverse effects. Always inform your doctor and pharmacist about all medications you are currently taking, have recently taken, or plan to take, including over-the-counter drugs, herbal supplements, and vitamins. The table below summarizes the most important known interactions.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Non-selective MAO inhibitors (isocarboxazid, phenelzine) | Risk of hypertensive crisis | Contraindicated. Stop MAO inhibitor at least 14 days before starting levodopa |
| Antipsychotics (haloperidol, risperidone, chlorpromazine, fluphenazine) | Dopamine receptor blockade reduces levodopa efficacy | Avoid if possible. If needed, use quetiapine or clozapine (atypical antipsychotics with less D2 blockade) |
| Metoclopramide | Central dopamine antagonism; reduces levodopa effectiveness and worsens parkinsonism | Avoid. Use domperidone as an alternative antiemetic (does not cross blood-brain barrier) |
| Isoniazid | Inhibits DOPA decarboxylase; reduces levodopa conversion to dopamine | Monitor closely; dose adjustment may be required |
| Iron supplements | Chelates levodopa in the gut, reducing absorption by up to 50% | Separate doses by at least 2 hours |
Moderate Interactions and Co-prescribed Medications
| Interacting Drug | Effect | Clinical Guidance |
|---|---|---|
| Selective MAO-B inhibitors (rasagiline, selegiline, safinamide) | Increases dopamine levels; may potentiate dyskinesias | Commonly co-prescribed. Monitor for dyskinesias; levodopa dose reduction may be needed |
| COMT inhibitors (entacapone, tolcapone, opicapone) | Prolongs levodopa half-life; increases brain exposure | Standard adjunct therapy. Reduce levodopa dose by 10-30% when adding COMT inhibitor |
| Anticholinergics (orphenadrine, trihexyphenidyl) | Additive antiparkinsonian effect; may delay levodopa absorption | Used together cautiously. Monitor for increased confusion, especially in elderly patients |
| Tricyclic antidepressants (clomipramine, desipramine, doxepin) | May potentiate orthostatic hypotension; rare hypertensive episodes reported | Monitor blood pressure closely when starting or adjusting doses |
| Antihypertensives | Additive hypotensive effect; increased risk of orthostatic hypotension | Dose adjustment of antihypertensive may be needed |
| Amantadine | Synergistic antiparkinsonian effect; may increase dyskinesias | Used to manage dyskinesias but monitor for psychiatric side effects |
| High-protein meals | Large neutral amino acids compete with levodopa for intestinal absorption and blood-brain barrier transport | Take levodopa 30 minutes before or 1 hour after meals; consider protein redistribution diet |
Dietary protein can significantly affect levodopa absorption and brain delivery. Large neutral amino acids from protein-rich foods (meat, fish, dairy, eggs, legumes) compete with levodopa for absorption in the small intestine and for transport across the blood-brain barrier. To optimize response, take levodopa 30 minutes before meals or 1 hour after meals. Some patients benefit from a protein redistribution diet, where most daily protein intake is consumed at the evening meal, when motor function is less critical.
What Is the Correct Dosage of Levodopa?
Levodopa dosing requires careful individualization because the optimal dose varies considerably between patients depending on disease severity, duration of treatment, individual sensitivity, and concurrent medications. Treatment always follows the principle of "start low, go slow" to minimize side effects while achieving adequate motor symptom control. All doses described below refer to the levodopa component; the decarboxylase inhibitor (carbidopa or benserazide) is included in a fixed ratio in each formulation.
Adults — Oral Formulations
Starting Dose
Begin with 50-100 mg levodopa (with decarboxylase inhibitor) two to three times daily. Take with or shortly after a meal during the initial phase to reduce nausea. After nausea subsides, taking the medication 30 minutes before meals can improve absorption.
Dose Titration
Increase the dose gradually by 50-100 mg every 3-7 days until satisfactory symptom control is achieved or side effects become limiting. The dose is adjusted based on clinical response, balancing motor improvement against the development of dyskinesias or other adverse effects.
Maintenance Dose
The typical maintenance dose is 300-800 mg of levodopa per day, divided into 3-5 doses throughout the day. Some patients with advanced disease may require higher doses, up to 1000-1500 mg daily, though this increases the risk of motor complications. The total daily dose should be divided to maintain more stable plasma levels.
Inhaled Levodopa (Inbrija) — Off-Period Rescue
Dose Per Off-Period
Inhale the contents of 2 capsules (total 66 mg levodopa) at the onset of each off-period. Use the provided Inbrija inhaler device. Do not swallow the capsules. The two capsules should be inhaled one after the other within 10 minutes.
Maximum Daily Dose
Do not exceed 10 capsules (330 mg) per day, which corresponds to a maximum of 5 off-period treatments per day. Inhaled levodopa is used in addition to regular oral levodopa therapy, not as a replacement.
Children and Adolescents
Levodopa is not recommended for patients under 18 years of age for the treatment of Parkinson's disease, as idiopathic Parkinson's disease does not occur in this age group. In rare pediatric movement disorders such as DOPA-responsive dystonia (Segawa disease), levodopa may be prescribed by specialist neurologists at individually determined doses, typically much lower than adult Parkinson's disease doses (starting at 1 mg/kg/day).
Elderly Patients
Elderly patients (over 65 years) are generally more susceptible to the side effects of levodopa, particularly orthostatic hypotension, confusion, hallucinations, and drowsiness. Dose titration should be especially gradual in this population, starting with the lowest recommended dose and increasing more slowly. Elderly patients are also at higher risk for impulse control disorders and psychiatric complications. Regular monitoring is essential.
Missed Dose
If you miss a dose of oral levodopa, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. For inhaled levodopa (Inbrija), use it only during off-periods; if the off-period has passed, wait until the next off-period to use it.
Overdose
If you have taken too much levodopa or if someone accidentally ingests the medication, seek immediate medical attention. Symptoms of overdose may include confusion, agitation, insomnia, nausea, vomiting, and cardiac arrhythmias (abnormally fast or slow heartbeat). There is no specific antidote; treatment is supportive and symptomatic. In hospital, electrocardiographic monitoring may be initiated.
What Are the Side Effects of Levodopa?
Like all medications, levodopa can cause side effects, although not everyone who takes it will experience them. The nature and severity of side effects often depend on the dose, duration of treatment, disease stage, and individual patient factors. Some side effects are more common at the start of therapy and may improve as the body adjusts, while others may develop or worsen with long-term use. Understanding the frequency categories helps put the risk into perspective.
Very Common
- Nausea
- Dyskinesias (involuntary movements) — especially with long-term use
- Cough (inhaled formulation)
Common
- Vomiting
- Loss of appetite
- Dizziness and orthostatic hypotension (low blood pressure on standing)
- Somnolence (excessive drowsiness)
- Insomnia
- Vivid dreams and nightmares
- Hallucinations
- Confusion
- Motor fluctuations (wearing-off, on-off phenomena)
- Upper respiratory tract infections (inhaled formulation)
- Discolored sputum or nasal discharge (inhaled formulation)
- Throat irritation (inhaled formulation)
- Falls
Uncommon
- Depression and anxiety
- Agitation and paranoia
- Impulse control disorders (pathological gambling, hypersexuality, compulsive shopping, binge eating)
- Cardiac arrhythmias (irregular heartbeat)
- Gastrointestinal bleeding
- Peptic ulcer
- Muscle cramps and spasms
- Dark discoloration of urine
Rare / Frequency Not Known
- Neuroleptic malignant syndrome-like hyperpyrexia (upon sudden withdrawal)
- Seizures
- Hemolytic anemia, leukopenia, thrombocytopenia
- Melanoma
- Suicidal ideation
- Sudden sleep onset without warning
- Restless legs syndrome
- Dementia
- Horner's syndrome
- Priapism (prolonged painful erection)
- Angioedema (swelling of face, lips, tongue, throat)
- Henoch-Schönlein purpura
- Rhabdomyolysis
Contact emergency services or go to the nearest emergency department if you experience: angioedema (swelling of face, lips, tongue, or throat with difficulty breathing or swallowing); severe muscle rigidity with high fever and confusion (signs of neuroleptic malignant syndrome); blood in your stool or dark/tarry stools (signs of gastrointestinal bleeding); or severe chest pain with irregular heartbeat.
Motor Complications with Long-Term Use
One of the most significant clinical challenges with levodopa therapy is the development of motor complications over time. After approximately 5 years of treatment, up to 50% of patients experience these complications, which include:
- Wearing-off (end-of-dose deterioration): The beneficial effect of each dose becomes shorter, and symptoms return before the next dose is due. This is the most common motor complication and is related to the progressive loss of dopaminergic neurons and their ability to store and release dopamine.
- On-off phenomena: Unpredictable, sometimes sudden, fluctuations between periods of good motor function ("on") and periods of impaired mobility ("off"), which may not be clearly related to the timing of doses.
- Peak-dose dyskinesias: Involuntary, choreiform (dance-like) movements that occur when levodopa blood levels are at their highest, typically 1-2 hours after a dose.
- Diphasic dyskinesias: Abnormal movements that occur as levodopa levels are rising and falling, often affecting the legs.
- Freezing of gait: Sudden, brief episodes where the feet seem "glued to the floor," particularly when initiating walking, turning, or approaching doorways.
These complications are managed through various strategies including dose fractionation (smaller, more frequent doses), addition of COMT inhibitors (entacapone, opicapone) or MAO-B inhibitors (rasagiline, safinamide) to extend levodopa effect, use of extended-release formulations, rescue treatment with inhaled levodopa for off-periods, or in advanced cases, deep brain stimulation (DBS) surgery or continuous intestinal gel infusion (Duodopa).
How Should You Store Levodopa?
Proper storage of levodopa-containing medications is essential to maintain their potency and safety throughout the treatment period. All formulations should be kept out of the sight and reach of children. Do not use the medication after the expiration date printed on the packaging (the expiry date refers to the last day of that month).
Oral Tablets and Capsules
Store oral levodopa formulations at room temperature, not exceeding 25°C (77°F). Keep the tablets or capsules in their original packaging to protect them from moisture and light. Do not transfer the medication to other containers unless instructed by your pharmacist. If tablets appear discolored, crumbled, or damaged, do not use them and consult your pharmacist.
Inbrija Inhalation Capsules
Inbrija capsules require special storage precautions. Store at or below 25°C (77°F) in the original packaging. The capsules are sensitive to light and moisture and must be removed from the blister strip immediately before use. Do not use a capsule that appears crushed, damaged, or wet — discard it and use a new capsule. When you open a new carton, always use the inhaler device included in that carton. Dispose of the inhaler after all capsules in the carton have been used.
Disposal
Do not dispose of medications via household waste or through the sewage system. Return unused or expired medications to your local pharmacy for safe disposal. These measures help protect the environment and prevent accidental exposure.
What Does Levodopa Contain?
Active Ingredients
All levodopa formulations contain levodopa as the primary active ingredient, combined with a peripheral decarboxylase inhibitor to enhance bioavailability:
- Levodopa/Carbidopa (ratio 4:1 or 10:1): Available as Sinemet, Stalevo (also contains entacapone), and generic formulations. Common strengths include 100/25 mg, 250/25 mg, and 100/10 mg.
- Levodopa/Benserazide (ratio 4:1): Available as Madopark and generic formulations. Common strengths include 100/25 mg, 200/50 mg. Extended-release (depot) and dispersible (quick-release) formulations are also available.
- Levodopa for inhalation (Inbrija): Each hard capsule contains 42 mg levodopa, delivering 33 mg per dose through the inhaler mouthpiece. No decarboxylase inhibitor is included in the capsule; patients must already be on a regular levodopa/decarboxylase inhibitor regimen.
Inactive Ingredients (Excipients)
The specific excipients vary by product and manufacturer. For Inbrija inhalation capsules, the inactive ingredients include dipalmitoylphosphatidylcholine (DPPC, a lung surfactant component), sodium chloride, hypromellose, titanium dioxide (E 171), carrageenan, potassium chloride, carnauba wax, corn starch, shellac, black iron oxide (E 172), propylene glycol, and potassium hydroxide. Oral tablet formulations typically contain standard pharmaceutical excipients such as microcrystalline cellulose, starch, magnesium stearate, and various coating agents depending on the specific product.
If you have known allergies to any specific excipients, review the full ingredient list on your medication's patient information leaflet or consult your pharmacist before starting treatment.
Frequently Asked Questions About Levodopa
Levodopa is the most effective medication for treating the motor symptoms of Parkinson's disease, including tremor, stiffness (rigidity), and slowness of movement (bradykinesia). It is a dopamine precursor that crosses the blood-brain barrier and is converted into dopamine to replenish depleted stores in the brain. It is always combined with a decarboxylase inhibitor such as carbidopa or benserazide to prevent breakdown before reaching the brain. It is listed on the WHO Model List of Essential Medicines and has been the gold standard of Parkinson's treatment for over 50 years.
Common side effects of levodopa include nausea, vomiting, dizziness, orthostatic hypotension (low blood pressure when standing), and involuntary movements called dyskinesias. Long-term use is associated with motor fluctuations including "wearing-off" (end-of-dose deterioration) and "on-off" phenomena. Psychiatric side effects such as hallucinations, confusion, and impulse control disorders may also occur, particularly in elderly patients. Taking levodopa with food during the initial treatment period can help reduce nausea.
Levodopa is always given in combination with a peripheral decarboxylase inhibitor (carbidopa or benserazide) to prevent the enzyme DOPA decarboxylase from converting levodopa to dopamine outside the brain. Without this combination, up to 95% of levodopa would be converted peripherally, leading to significant nausea, vomiting, and cardiovascular side effects while reducing the amount available to the brain. The combination increases brain bioavailability from approximately 5% to 30-40% and allows lower doses to be effective.
Off-periods are times when a patient's regular Parkinson's medication does not adequately control symptoms, leading to increased difficulty with movement, stiffness, or tremor. They typically occur as the disease progresses and are related to fluctuations in levodopa blood levels. Inhaled levodopa (brand name Inbrija) provides rapid delivery of levodopa through the lungs for rescue treatment during off-periods, with effects beginning within 10-15 minutes. It is used alongside regular oral levodopa therapy, not as a replacement. The recommended dose is 2 capsules (66 mg) per off-period, up to 5 times daily.
No, levodopa should never be stopped abruptly. Sudden withdrawal can cause a dangerous condition similar to neuroleptic malignant syndrome, with symptoms including high fever, severe muscle rigidity, altered consciousness, rapid heart rate, and unstable blood pressure. This condition, called hyperpyrexia or parkinsonism-hyperpyrexia syndrome, is a medical emergency that requires immediate hospitalization. Any dose reduction should be gradual and supervised by your doctor. Even temporary interruptions (for example, before surgery) must be carefully managed.
The response to levodopa changes over time due to the progressive nature of Parkinson's disease rather than true drug tolerance. As more dopaminergic neurons are lost, the brain's capacity to store and regulate dopamine release from levodopa diminishes. After approximately 5 years of treatment, up to 50% of patients develop motor complications including wearing-off (end-of-dose deterioration), on-off fluctuations, and dyskinesias. These are managed through dose adjustments, addition of adjunct medications (COMT inhibitors, MAO-B inhibitors), extended-release formulations, or advanced therapies such as deep brain stimulation or continuous intestinal gel infusion.
References
This article is based on peer-reviewed medical literature, international clinical guidelines, and approved prescribing information. All medical claims are supported by evidence level 1A where available.
- Movement Disorder Society Evidence-Based Medicine Review. "Treatments for the motor symptoms of Parkinson's disease." Movement Disorders, 2023. DOI: 10.1002/mds.29387
- European Medicines Agency (EMA). "Inbrija (levodopa) Summary of Product Characteristics." EMA/CHMP, last updated 2025.
- National Institute for Health and Care Excellence (NICE). "Parkinson's disease in adults: diagnosis and management." NICE guideline [NG71], updated 2024.
- World Health Organization. "WHO Model List of Essential Medicines — 23rd List." WHO, 2023.
- Fahn S, Oakes D, Shoulson I, et al. "Levodopa and the progression of Parkinson's disease." New England Journal of Medicine, 2004; 351(24): 2498-2508.
- Armstrong MJ, Okun MS. "Diagnosis and Treatment of Parkinson Disease: A Review." JAMA, 2020; 323(6): 548-560. DOI: 10.1001/jama.2019.22360
- LeWitt PA, Hauser RA, Pahwa R, et al. "Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial." The Lancet Neurology, 2019; 18(2): 145-154.
- Olanow CW, Stern MB, Sethi K. "The scientific and clinical basis for the treatment of Parkinson disease." Neurology, 2009; 72(21 Suppl 4): S1-136.
- Connolly BS, Lang AE. "Pharmacological treatment of Parkinson disease: a review." JAMA, 2014; 311(16): 1670-1683.
- British National Formulary (BNF). "Levodopa with benserazide" and "Levodopa with carbidopa." NICE/BNF, 2025.
Editorial Team
This article has been written and reviewed by iMedic's medical editorial team, which includes specialists in neurology, movement disorders, and clinical pharmacology. Our content follows international medical guidelines and the GRADE evidence framework.
iMedic Medical Editorial Team — Specialists in Neurology and Clinical Pharmacology with expertise in movement disorders and Parkinson's disease therapeutics.
iMedic Medical Review Board — Independent panel of medical experts who review all content according to WHO, EMA, FDA, and MDS guidelines.
Last medical review: | Published:
Our editorial process ensures accuracy, currency, and impartiality. We have no commercial funding and accept no pharmaceutical sponsorship. Read more about our editorial standards and medical team.